

REMARKS

I. Response to Restriction Requirement

1. In response to the Restriction Requirement dated October 26, 2007, Applicant provisionally elects to prosecute the claims of the method wherein the antibody is a human antibody as recited by claim 6, with traverse.


2. Applicant respectfully traverses the restriction requirement. MPEP §803 states that the two criteria for restriction between patentably distinct inventions (1) the inventions must be independent or distinct as claimed, and (2) there must be a serious burden on the Examiner if restriction is required.

Here the Examiner has not shown that there would be a serious burden on the Examiner to search the claimed antibodies wherein the antibody is a human antibody as recited in claim 6 or a humanized antibody as recited in claim 7. As a search of all the claims seems to have already been conducted, based on the Office Action dated December 18, 2006, the need for restriction at this time seems unclear. Further, as claims 6 and 7 are written to be dependent on claim 1, they should both be allowable if their parent claim if it is allowable. Applicant respectfully requests removal of the restriction requirement claims 6 and 7.

II. Conclusion

3. In the event that the Examiner wishes to discuss any aspect of this communication, please contact the undersigned Attorney at the telephone number provided below.

Respectfully submitted,



Nicholas I. Slepchuk, Jr.
Attorney for the Applicants
Reg. No. 32,174

Date: November 1, 2007

Pfizer Inc.
Patent Department
MS8260-1611
Eastern Point Road
Groton, CT 06340
(860) 715-0081